The Basic Principles of Treatment of Ankylosing Spondylitis (Bechterew's Disease)

Erdes, S.

doi:10.14412/1995-4484-2013-686-95

Cited by 4 publications

(2 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Прогрессирование заболевания в первую оче-редь связано с пролиферацией костной ткани, проявляющейся в основном ростом синдесмо-фитов (и/или энтезофитов) и процессом анки-лозирования, как правило, КПС [1,2].…”

unclassified

“…Появив-шийся за последние полтора десятилетия но-вый класс лекарственных средств -ингиби-торы фактора некроза опухоли α (иФНОα) -обеспечивают быстрое клиническое улучше-ние и положительное влияние на качество жизни при СпА [2][3][4][5][6]. Кроме того, имеются данные, что при длительном их применении замедляется прогрессирование болезни [7].…”

unclassified

See 1 more Smart Citation

TUMOR NECROSIS FACTOR-α INHIBITORS IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS

Lapshina¹,

Дубинина²,

Бадокин³

et al. 2016

rsp

View full text Add to dashboard Cite

The paper provides guidelines for the use of tumor necrosis factor-α (TNF-α) inhibitors in the treatment of patients with axial spondyloarthritis (axSpA), including ankylosing spondylitis. It gives data on the efficacy of TNF-α inhibitors in patients with non-radiographic axSpA. By using international and Russian guidelines, the authors lay down indications for this therapy and criteria for evaluation of its efficiency and safety. Key words: axial spondyloarthritis; ankylosing spondylitis; tumor necrosis factor-α (TNF-α) inhibitors; efficacy; safety. For reference: Lapshina SA, Dubinina TV, Badokin VV, et al. Tumor necrosis factor-α inhibitors in the treatment of axial spondyloarthritis, including ankylosing spondylitis.

show abstract

unclassified

TUMOR NECROSIS FACTOR-α INHIBITORS IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS

Lapshina¹,

Дубинина²,

Бадокин³

et al. 2016

rsp

View full text Add to dashboard Cite

show abstract

Cost-effectiveness study of treatment with biologic disease-modifying antirheumatic drugs in adult patients with active ankylosing spondylitis

Древаль

2021

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Objective: to conduct a cost-effectiveness study of major biologic disease-modifying antirheumatic drugs (bDMARDs) used for the treatment of ankylosing spondylitis (AS) in Russian health care system with the focus on the new effective drug netakimab (NTK).Patients and methods. Based on the available meta-analysis, a Markov model for therapy was constructed using reference drugs. Then, based on the simulation results, a Cost-Effectiveness Analysis (CEA) and a Budget Impact Analysis (BIA) were carried out. The robustness of the result has been confirmed by several sensitivity analyzes.Results and discussion. NTK showed an advantage in CEA, including the cases when the direct costs of therapy were lower for the reference drug (which shows the greater efficacy of NTK). According to the BIA, the extension of NTK administration in naive patients was consistently associated with a decrease in the budgetary burden. Sensitivity analyzes confirmed the robustness of the result.Conclusion. NTK has clinical and economic advantage in the treatment of AS, it is attractive in terms of both patient's and health care benefit in general. More extensive use of NTK can save more than 5 billion RUB.

show abstract

Difficult airway in a surgical patient with ankylosing spondylitis (Bechterew's disease): clinical case

Sokolov,

Potapov,

Ganert

et al. 2024

PoMPh

View full text Add to dashboard Cite

A difficult airway is a life-threatening clinical situation in which a trained anesthesiologist experiences difficulty ventilating the upper airway with a tight mask, difficulty intubation the trachea, or both. This is an important socio-economic problem that makes a significant contribution to the structure of intraoperative mortality and disability of patients. A clinical observation of difficult airways in a patient with ankylosing spondylitis who was scheduled to have a brain tumor removed is presented.

show abstract

The Basic Principles of Treatment of Ankylosing Spondylitis (Bechterew's Disease)

Cited by 4 publications

References 55 publications

TUMOR NECROSIS FACTOR-α INHIBITORS IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS

TUMOR NECROSIS FACTOR-α INHIBITORS IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS

Cost-effectiveness study of treatment with biologic disease-modifying antirheumatic drugs in adult patients with active ankylosing spondylitis

Difficult airway in a surgical patient with ankylosing spondylitis (Bechterew's disease): clinical case

Contact Info

Product

Resources

About